Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company - a16z Podcast Recap

Podcast: a16z Podcast

Published: 2026-02-16

Duration: 58 minutes

Guests: Vasant Narasimhan

Summary

Novartis CEO Vasant Narasimhan discusses the strategic transformation of Novartis from a conglomerate into a focused medicines company, unlocking significant value. He highlights the role of advanced platform technologies and AI in this evolution.

What Happened

Novartis successfully transformed from a sprawling conglomerate into a streamlined medicines company, unlocking approximately $180 billion in value. Under the leadership of CEO Vasant Narasimhan, Novartis spun off three public companies, including its consumer health business and Alcon, to focus on biopharmaceuticals.

The company now concentrates on four key disease areas: oncology, immunology, neuroscience, and cardio renal, supported by three advanced platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. Zolgensma, a groundbreaking gene therapy developed by Novartis for spinal muscular atrophy, exemplifies their success, boasting reimbursement in 48 countries despite its $2 million price tag.

Narasimhan's background includes work in public health, which informs his leadership at Novartis. The company, formed from the merger of Sandoz and Ciba-Geigy in 1996, now operates in over 100 countries with $55 billion in sales and a $300 billion market cap, emphasizing its 'Pure Play Medicines Company' vision.

In terms of technology, Novartis sees potential in AI to enhance drug discovery and increase the probability of success in drug development. The company collaborates with isomorphic labs on using AlphaFold 3 to target 'undruggable' targets and with Palantir to manage R&D data.

The rise of China's biotech industry poses a competitive challenge, with faster approval times for first-in-human studies and increased licensing activities. Narasimhan stresses the importance of maintaining a competitive edge in the U.S. biotechnology sector.

Novartis's culture focuses on being 'unbossed,' inspired, and curious, which Narasimhan believes naturally improves the organizational culture. He notes that Chemical Manufacturing and Controls (CMC) work is critical in biotech partnerships and often underinvested in startups.

Key Insights

• Novartis transformed itself by spinning off three public companies, including Alcon, to focus solely on biopharmaceuticals, creating approximately $180 billion in value. This move streamlined the 250-year-old company, allowing it to concentrate on high-impact areas like oncology and immunology.
• The development of Zolgensma, a $2 million gene therapy for spinal muscular atrophy, showcases Novartis's commitment to advanced platform technologies. Despite its steep price, Zolgensma has achieved reimbursement in 48 countries, highlighting its global impact and the strategic importance of gene therapies.
• Novartis collaborates with isomorphic labs and uses AI technologies like AlphaFold 3 to tackle 'undruggable' targets in drug development. This approach aims to enhance drug discovery success rates by leveraging cutting-edge computational tools.
• China's biotech industry challenges the U.S. with its rapid approval processes and increased licensing activities. Novartis CEO Vasant Narasimhan emphasizes the need for the U.S. to maintain its competitive edge, suggesting that the pace of innovation in China could alter global dynamics in drug development.

Key Questions Answered

How did Novartis unlock $180 billion in value?

Novartis unlocked $180 billion in value by transforming from a conglomerate into a focused medicines company, spinning off three public companies, including its consumer health business and Alcon.

What is Zolgensma, and why is it significant?

Zolgensma is a gene therapy developed by Novartis to treat spinal muscular atrophy. It is significant due to its high cost-effectiveness, despite a $2 million price tag, and its reimbursement in 48 countries.

What challenges does the rise of China's biotech industry pose?

China's biotech industry challenges U.S. companies with faster approval times for first-in-human studies and more licensing activities, necessitating a competitive response from the U.S. sector.